6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For
the
month of January, 20006.
Commission
File Number ________________
Novogen
Limited
(Translation
of registrant’s name into English)
140
Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes o No
o
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
82-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Novogen
Limited
(Registrant)
Date January
11, 2006 /s/
Ron Erratt
Ronald
Lea Erratt
Company
Secretary
ASX
& MEDIA RELEASE
10
JANUARY, 2006
GLYCOTEX,
INC. POSTPONES PROPOSED INITIAL PUBLIC OFFERING OF ITS COMMON STOCK
UNITS
Pharmaceutical
company Novogen Limited announced today that Glycotex, Inc., its US subsidiary,
is withdrawing its Form S-1 Registration Statement from the Securities Exchange
Commission and is postponing the initial public offering of its common stock
units.
Glycotex
wishes to further advance the development program for its wound healing and
tissue repair product candidates, and currently intends to re-file a
registration statement later in 2006.
Glycotex,
Inc. is a clinical stage biopharmaceutical company focused on discovering and
developing a novel class of drugs for human wound healing and tissue repair.
Novogen
(Nasdaq: NVGN ASX: NRT) is a world leader in the research and development of
drugs derived from its phenolic technology platform. The Company manages its
international research and development programs using the expertise and clinical
research capabilities of universities and hospitals in the US, Australia and
other key international locations. The oncology compound phenoxodiol is being
developed by the Company's listed subsidiary Marshall Edwards Inc. (Nasdaq:
MSHL).
Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials. After the results of these trials are submitted in a new drug
application to the FDA, the FDA must approve the drug as safe and effective
before marketing can take place.
Statements
included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. You should be aware
that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in clinical
trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for
the
development, manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our patents
or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.
ISSUED
FOR : NOVOGEN
LIMITED
LISTINGS : ASX
(CODE NRT), NASDAQ (CODE NVGN).
FOR
FURTHER MR
CHRISTOPHER NAUGHTON, MANAGING DIRECTOR, NOVOGEN LIMITED
INFORMATION : TEL
(02) 9878
0088 http://www.novogen.com
ISSUED
BY : WESTBROOK
COMMUNICATIONS
CONTACT:
DAVID REID TEL
(02) 9231 0922 OR 0417 217 157